Pancreatic cancer has long been one of medicine’s most stubborn adversaries. A disease that kills roughly 80 percent of those diagnosed within a year, it has resisted decades of research and treatment advances. But a clinical trial published in May 2026 suggests that a new genetically targeted drug — daraxonrasib — could fundamentally change how this cancer is treated, offering patients a meaningful survival advantage where little existed before.
Key Developments
The phase 1/2 trial, conducted across multiple centres in the United States and published in the New England Journal of Medicine, enrolled 168 patients with advanced, RAS-mutant metastatic pancreatic cancer. All participants had previously been treated with at least one line of chemotherapy. They received daraxonrasib as a daily oral medication.
The results were striking. Patients taking daraxonrasib lived three to four times longer without disease progression compared to those on standard second-line chemotherapy — roughly eight to nine months versus two to three months. The drug belongs to a new class of precision medicines called RAS(ON) multi-selective inhibitors, designed to target and kill cancer cells that carry the specific RAS mutations present in more than 90 percent of pancreatic tumours.
“For the first time, we have a targeted therapy relevant to nearly all patients with advanced pancreatic cancer,” said Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and the study’s lead investigator. “This represents a substantial shift in how this disease could be treated.”
The significance of the breakthrough lies partly in the history of the RAS gene itself. KRAS was long considered “undruggable” — a tumour-driving gene that seemed beyond the reach of medicine. Around ten years ago, advances in chemistry allowed researchers to develop the first RAS inhibitors. Two are now approved for lung and colorectal cancers, but they target a RAS mutation found only rarely in pancreatic cancer. Daraxonrasib is the first to work against the RAS mutations that dominate pancreatic tumours.
One patient who benefited from the drug was Vicky Stinson, a 65-year-old retired landscape architect from Flagstaff, Arizona, who was diagnosed with stage 3 pancreatic cancer in 2024 and given months to live. She enrolled in the daraxonrasib trial and remained on the drug for 13 months. Unlike chemotherapy, which requires hours-long infusions, daraxonrasib is taken as a single daily pill. Stinson reported far fewer side effects — she experienced mild acne on her face, neck and back, but retained enough energy to continue hiking.
The trial’s adverse effects included rash, mouth inflammation and nausea, with roughly a third of patients experiencing moderate to severe skin or gastrointestinal reactions. No patients discontinued the trial as a result of side effects. A phase 3 trial — RASolute 302 — is now underway to confirm these findings in a larger patient group.
Pancreatic cancer kills roughly 66,000 Americans annually. The disease’s location — hidden behind other organs — makes early detection nearly impossible. Its tumour cells behave more like scattered grains of sand than a solid mass, spreading easily through the bloodstream. Even when detected, the disease often resists treatment because tumours insulate themselves in a protective cocoon that shields them from chemotherapy and blood vessels alike.
The overall five-year survival rate for pancreatic cancer stands at just 13 percent, compared to 70 percent for cancers overall, where advances in immunotherapy, genetics and AI imaging have transformed outcomes. Researchers say daraxonrasib could close that gap if the phase 3 trial confirms its benefits.
“This is not about replacing chemotherapy entirely — it is about finally having a targeted alternative that goes after the root genetic driver of this disease,” said Dr. Rajesh Ramanathan, a surgical oncologist at Banner MD Anderson Cancer Center who was not involved in the study.
The drug’s developer, Revolution Medicine, announced that regulatory review proceedings are expected to begin in late 2026. Patient advocacy groups cautiously welcomed the data, noting that the field has seen promising results collapse in phase 3 trials before — but called the findings the most encouraging development in pancreatic cancer treatment in years.
